Valley is aware of the nationwide supply disruption of IV fluid solution due to Hurricane Helene, and wants to reassure the community that steps have been taken to ensure the situation will have no negative impact on our patients and the community.
Clinical Trials
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
A021806
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Principal Investigator(s): Kevin Wood, MD
Status: Open and enrolling
A021806
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
Principal Investigator(s): Kevin Wood, MD
Status: Open and enrolling
A081801 Alchemist
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Principal Investigator(s): Jason W. Suh, MD
Status: Open and enrolling
ACCLAIM 1
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
ASTEFANIA
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Principal Investigator(s): Amanda J. Podolski, MD
Status: Open and enrolling
BPM31510
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Principal Investigator(s): Rupa G. Juthani, MD
Status: Open and enrolling
DRAMMATIC (S1803)
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator(s): Jason W. Suh, MD
Status: Closed to Enrollment, Patients in Follow-Up
GLORIOSA
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA).
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling